IFRX – InflaRx N.V.
InflaRx N.V.IFRX
$1.66Name : InflaRx N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $244,506,144.00
EPSttm : -0.73
InflaRx N.V.
$1.66
2.92%$0.05
IFRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.7
Margin Of Safety %
Put/Call OI Ratio
0.3
EPS Next Q Diff
0.04
EPS Last/This Y
0.49
EPS This/Next Y
-0.07
Price
1.66
Target Price
7.91
Analyst Recom
1.5
Performance Q
78.49
Upside
N/A
Beta
2.51
Ticker: IFRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | IFRX | 2.52 | 0.20 | 0.00 | 6010 |
| 2026-05-12 | IFRX | 2.44 | 0.20 | 20.00 | 5978 |
| 2026-05-13 | IFRX | 2.53 | 0.20 | 0.03 | 5978 |
| 2026-05-14 | IFRX | 2.39 | 0.20 | 0.06 | 5974 |
| 2026-05-15 | IFRX | 2.48 | 0.20 | 2.28 | 5987 |
| 2026-05-18 | IFRX | 2.5 | 0.05 | 0.05 | 4529 |
| 2026-05-19 | IFRX | 2.38 | 0.05 | 20.00 | 5181 |
| 2026-05-20 | IFRX | 2.45 | 0.10 | 0.00 | 5371 |
| 2026-05-21 | IFRX | 2.48 | 0.10 | 8.71 | 5380 |
| 2026-05-22 | IFRX | 2.62 | 0.11 | 1.14 | 5443 |
| 2026-05-26 | IFRX | 2.75 | 0.17 | 2.17 | 5758 |
| 2026-05-27 | IFRX | 2.58 | 0.25 | 0.02 | 6270 |
| 2026-05-28 | IFRX | 2.39 | 0.25 | 250.00 | 6283 |
| 2026-05-29 | IFRX | 2.4 | 0.30 | 5.25 | 6533 |
| 2026-06-02 | IFRX | 2.19 | 0.31 | 0.69 | 6554 |
| 2026-06-03 | IFRX | 2.05 | 0.31 | 0.10 | 6554 |
| 2026-06-04 | IFRX | 2 | 0.31 | 0.05 | 6565 |
| 2026-06-05 | IFRX | 1.85 | 0.31 | 3.05 | 6584 |
| 2026-06-08 | IFRX | 1.72 | 0.30 | 0.15 | 6646 |
| 2026-06-09 | IFRX | 1.66 | 0.30 | 999.99 | 6665 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | IFRX | 2.52 | 41.7 | 4.6 | -0.65 |
| 2026-05-12 | IFRX | 2.44 | 41.7 | 2.3 | -0.65 |
| 2026-05-13 | IFRX | 2.53 | 41.7 | -2.4 | -0.65 |
| 2026-05-14 | IFRX | 2.39 | 41.7 | 6.5 | -0.65 |
| 2026-05-15 | IFRX | 2.48 | 41.7 | 1.7 | -0.22 |
| 2026-05-18 | IFRX | 2.49 | 76.2 | 3.6 | -0.22 |
| 2026-05-19 | IFRX | 2.39 | 76.2 | 6.0 | -0.22 |
| 2026-05-20 | IFRX | 2.44 | 76.2 | 2.3 | -0.22 |
| 2026-05-21 | IFRX | 2.48 | 76.2 | 3.4 | -0.22 |
| 2026-05-22 | IFRX | 2.62 | 73.8 | 0.9 | -0.30 |
| 2026-05-26 | IFRX | 2.74 | 73.8 | 1.4 | -0.30 |
| 2026-05-27 | IFRX | 2.58 | 73.8 | 7.3 | -0.30 |
| 2026-05-28 | IFRX | 2.39 | 73.8 | 7.8 | -0.30 |
| 2026-05-29 | IFRX | 2.40 | 73.8 | 4.0 | -0.30 |
| 2026-06-01 | IFRX | 2.28 | 73.8 | 6.7 | -0.30 |
| 2026-06-02 | IFRX | 2.19 | 73.8 | 6.2 | -0.30 |
| 2026-06-03 | IFRX | 2.05 | 73.8 | 7.3 | -0.30 |
| 2026-06-04 | IFRX | 2.00 | 73.8 | 5.4 | -0.30 |
| 2026-06-05 | IFRX | 1.84 | 73.8 | 7.9 | -0.30 |
| 2026-06-08 | IFRX | 1.72 | 73.8 | 7.2 | -0.30 |
| 2026-06-09 | IFRX | 1.66 | 73.8 | 5.4 | -0.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | IFRX | 0.00 | -0.61 | 2.66 |
| 2026-05-12 | IFRX | 0.00 | -0.61 | 2.93 |
| 2026-05-13 | IFRX | 0.00 | -0.61 | 2.93 |
| 2026-05-14 | IFRX | 0.00 | -0.61 | 2.93 |
| 2026-05-15 | IFRX | 0.00 | -0.61 | 2.93 |
| 2026-05-18 | IFRX | 0.00 | -1.00 | 3.73 |
| 2026-05-19 | IFRX | 0.00 | -1.00 | 3.73 |
| 2026-05-20 | IFRX | 0.00 | -1.00 | 3.73 |
| 2026-05-21 | IFRX | 0.00 | -1.00 | 3.73 |
| 2026-05-22 | IFRX | 0.00 | -1.00 | 3.73 |
| 2026-05-26 | IFRX | 0.00 | -0.48 | 3.73 |
| 2026-05-27 | IFRX | 0.00 | -0.48 | 3.73 |
| 2026-05-28 | IFRX | 0.00 | -0.48 | 11.30 |
| 2026-05-29 | IFRX | 0.00 | -0.48 | 0 |
| 2026-06-02 | IFRX | 0.00 | -0.47 | 5.55 |
| 2026-06-03 | IFRX | 0.00 | -0.47 | 5.55 |
| 2026-06-04 | IFRX | 0.00 | -0.47 | 4.70 |
| 2026-06-05 | IFRX | 0.00 | -0.47 | 4.70 |
| 2026-06-08 | IFRX | 0.00 | -0.47 | 4.70 |
| 2026-06-09 | IFRX | 0.00 | -0.47 | 4.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.09
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
-0.47
Beta
2.51
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
22
Growth Score
23
Sentiment Score
52
Actual DrawDown %
77.1
Max Drawdown 5-Year %
-88
Target Price
7.91
P/E
Forward P/E
PEG
P/S
P/B
2.82
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
-0.3
EPS Next Y. (Est.)
-0.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.27
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.35
EBIT Estimation
5.4
◆
IFRX
Healthcare
$1.66
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34
Range 1M
5.5%
Sup Dist
1.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
55.8%
EPS NY
-35.4%
52W%
41.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+376.5% upside
Upside
+376.5%
Quality
22
InflaRx N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 65
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
IFRX
Latest News
—
Caricamento notizie per IFRX…
stock quote shares IFRX – InflaRx N.V. Stock Price stock today
news today IFRX – InflaRx N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch IFRX – InflaRx N.V. yahoo finance google finance
stock history IFRX – InflaRx N.V. invest stock market
stock prices IFRX premarket after hours
ticker IFRX fair value insiders trading